Skip to main content

and
  1. Article

    Open Access

    Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens

    Dolutegravir/lamivudine (DTG/3TC) is a 2-drug regimen for HIV-1 treatment with long-term efficacy and good tolerability comparable to 3- or 4-drug regimens. This study evaluated DTG/3TC cost versus other stand...

    Julie Priest, Guillaume Germain, François Laliberté in Infectious Diseases and Therapy (2023)

  2. Article

    Open Access

    Real-World Effectiveness of Newly Initiated Systemic Therapy for Atopic Dermatitis in the United States: A Claims Database Analysis

    Atopic dermatitis (AD) is associated with significant quality-of-life and economic burdens. Real-world evidence is needed to identify optimal treatment pathways for AD. Here we evaluate real-world effectivenes...

    Jashin J. Wu, Marie-Hélène Lafeuille, Bruno Emond, Iman Fakih in Advances in Therapy (2022)

  3. Article

    Open Access

    Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database

    For many, atopic dermatitis (AD) is not adequately controlled with topical regimens. This analysis examined treatment using advanced therapies and associated costs.

    Lawrence F. Eichenfield, Marco DiBonaventura, Jason Xenakis in Dermatology and Therapy (2020)